Evidence map›Paper›PMID 31463895›Full record

ArticleIrish journal of medical science2020

Clinical outcomes of patients with pure small cell carcinoma of the urinary bladder.

Gokmen Umut Erdem, Mutlu Dogan, Aydin Aytekin, Suleyman Sahin, Havva Yeşil Cinkir, Abdullah Sakin, Melike Ozcelik, Oktay Bozkurt, Emel Sezer, Nebi Serkan Demirci and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Irish journal of medical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gokmen Umut ErdemDepartment of Medical Oncology, Kocaeli Derince Training and Research Hospital, 41310, Kocaeli, Turkey. gokmenumut@hotmail.com.
Mutlu DoganDepartment of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkey.
Aydin AytekinDepartment of Medical Oncology, Medical Faculty of Gazi University, Ankara, Turkey.
Suleyman SahinDepartment of Medical Oncology, Van Training and Research Hospital, Van, Turkey.
Havva Yeşil CinkirDepartment of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.
Abdullah SakinDepartment of Medical Oncology, Okmeydani Training and Research Hospital, İstanbul, Turkey.
Melike OzcelikDepartment of Medical Oncology, Kartal Training and Research Hospital, İstanbul, Turkey.
Oktay BozkurtDepartment of Medical Oncology, Medical Faculty of Erciyes University, Kayseri, Turkey.
Emel SezerDepartment of Medical Oncology, Medical Faculty of Mersin University, Mersin, Turkey.
Nebi Serkan DemirciDepartment of Medical Oncology, Tekirdag State Hospital, Tekirdag, Turkey.
Yakup BozkayaDepartment of Medical Oncology, Edirne State Hospital, Edirne, Turkey.
Nurullah ZenginDepartment of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThere is not yet a standardized approach to treat patients with small cell carcinoma of the bladder (SmCCB). This study aims to investigate the clinical features, treatment, and survival outcomes of patients with pure SmCCB. MATERIALS AND

methodsPatients diagnosed with SmCCB between January 2006 and September 2015 were retrospectively evaluated.

resultsA total of 34 patients with a median age of 63.0 years were included in the study, with a male to female ratio of 4.6:1.0. At the time of diagnosis, 22 patients (64.7%) had stage IV disease. At a median follow-up time of 12.7 months, 67.6% of patients died of bladder carcinoma, with an overall survival (OS) of 15.7 months for all patients. In the patients with stages I-III, nodal involvement, and distant metastases, the median OS was 31.8, 15.7, and 8.4 months, respectively (P = 0.005). Considering the survival rates of the patients (stages I-III) treated with surgery vs. local therapy, there was not a statistically significant difference (26.6 months and 31.8 months, P = 0.97, respectively). A multivariate analysis revealed that stage IV disease and poor ECOG performance status were associated with OS.

conclusionThe optimal treatment of SmCCB has been under debate. For the patients with advanced stage of disease (T4b, N+, M+), platinum containing chemotherapeutic agents should be preferred. Stage IV disease and poor ECOG performance status were associated with shorter OS.

Indexed as

AdultAgedAged, 80 and overCarcinoma, Small CellFemaleHumansMaleMiddle AgedRetrospective StudiesSurvival RateUrinary Bladder NeoplasmsBladderChemotherapyNeuroendocrine carcinomaSmall cell carcinomaSurgery

Identifiers

PMID31463895

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.